Cambridge Consultants Release: Teaching Old Drugs New Tricks

Published: Jul 23, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

July 23, 2013 – Innovative product development and technology consultancy firm Cambridge Consultants has collaborated with Clinigen Group to create a new way of identifying fresh market applications for drugs nearing the end of their product lifecycle.

Clinigen is committed to making further drug acquisitions, with a focus on rejuvenating product performance and extending product life by seeking new uses for drugs, extending their geographical sales footprint or reformulating them. Targeted products are niche, hospital-only, mature or end-of-lifecycle drugs.

As part of a six-month project, Cambridge Consultants built a bespoke acquisition database of 4,000 drugs, and screened and ranked them – identifying 150-180 potential targets. A shortlist was then drawn up of 20 hospital-only drugs that would be suitable for more detailed commercial discussions. The process included the analysis of clinical data and interviews with key opinion leaders.

Peter George, chief executive officer of Clinigen, said: “Identifying new drugs is vital to our unique business model and our mission to supply the right drug to the right patient at the right time. Working with Cambridge Consultants allowed us to ensure we developed the most robust and effective process that speeds up decision making to identify drugs to license and bring to market faster with consistent and measured market analysis.”

Clinigen has identified numerous product opportunities from the acquisition database, a number of which are being actively pursued.

Kate Hudson-Farmer, senior consultant at Cambridge Consultants, said: “New critical life-saving treatments are rarely found by serendipity and require strict search and selection processes. Combining these with our market analysis and strategy support, we’ve been able to help Clinigen breathe new life into old drugs.”

Cambridge Consultants develops breakthrough products, creates and licenses intellectual property, and provides business consultancy in technology critical issues for clients worldwide. For 50 years, the company has been helping its clients turn business opportunities into commercial successes, whether they are launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies. With a team of more than 400 staff, including engineers, scientists, mathematicians and designers, in offices in Cambridge (UK), Boston (USA) and Singapore, Cambridge Consultants offers solutions across a diverse range of industries including medical technology, industrial and consumer products, transport, energy, cleantech and wireless communications. For more information, visit:

Cambridge Consultants is part of Altran, a global leader in innovation and high-tech engineering consulting which supports companies in the creation and development of their new products and services. With a staff of 20,000 employees in more than 20 countries, the Group generated revenues of €1,456m in 2012. For more information, visit:

Clinigen Group is a specialty global pharmaceutical products and services business headquartered in the UK, with offices in the USA and Japan. The group has three operating businesses – Specialty Pharmaceuticals (Clinigen SP), Clinical Trials Supply (Clinigen CTS) and Global Access Programs (Clinigen GAP). Clinigen SP focuses on acquiring and in-licensing specialist, hospital-only medicines worldwide and commercializing them within niche markets. Clinigen CTS is dedicated to the global sourcing and supply of commercial medicines for clinical study use. And Clinigen GAP provides consultancy, development and implementation of programs to manage access to unlicensed, licensed or end-of-lifecycle products. For more information, visit:

Help employers find you! Check out all the jobs and post your resume.

Back to news